Interestingly, cGAS-STING is also implicated in the mechanism of action of PARPi used in the treatment of BRCA1 or BRCA2-positive breast and ovarian cancer–PARP inhibition results in the formation of cytosolic dsDNA, which activates cGAS-STING and leads to IFN- and T cell-mediated anti-tumor responses [188]. Here, CGAS is linked to ovarian cancer.